American journal of respiratory and critical care medicine
-
Am. J. Respir. Crit. Care Med. · May 2011
Multicenter Study Clinical TrialSerum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease.
There are no accepted blood-based biomarkers in chronic obstructive pulmonary disease (COPD). Pulmonary and activation-regulated chemokine (PARC/CCL-18) is a lung-predominant inflammatory protein that is found in serum. ⋯ Serum PARC/CCL-18 levels are elevated in COPD and track clinical outcomes. PARC/CCL-18, a lung-predominant chemokine, could be a useful blood biomarker in COPD.